PARP1 and ovarian cancer: Based on a chemotherapy regimen, a significantly poor OS was found with high PARP expression in breast cancer patients receiving neoadjuvant chemotherapy of anthracycline and taxane (HR = 1.98, 95% CI = 1.04–3.78 p = 0.04) and ovarian cancer patients receiving an adjuvant chemotherapy of paclitaxel and carboplatin (HR = 1.15, 95% CI = 1.03–1.28, p = 0.01) and platinum-based chemotherapy (agents not specified) (HR = 1.52, 95% CI = 1.15–2.02, p = 0.003) (Supplementary Figure S3A).